anti-GSK3 β, mAb (AF12E8)

CHF 322.00
In stock
YIF-LF-MA0315100 µlCHF 322.00
More Information
Product Details
Synonyms GSK3B; GSK-3 β; EC=; EC=; Glycogen Synthase Kinase-3 β; Serine/Threonine-Protein Kinase GSK3B
Product Type Monoclonal Antibody
Clone AF12E8
Isotype Mouse IgG1 κ
Immunogen/Antigen Recombinant human His-GSK3B protein purified from E. coli.
Application ELISA
Western Blot (1:2,000)
Crossreactivity Human
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Product Specification Sheet
Datasheet Download PDF
Glycogen synthase kinase-3β (GSK-3β) is a cytoplasmic serine/threonine protein kinase, which was initially identified as the kinase that phosphorylates glycogen synthase to inhibit glycogen synthesis. GSK3 β is a ubiquitously expressed kinase that regulates a wide variety of cellular functions including metabolism, gene expression and cytoskeletal integrity. Akt/PI3K reduces GSK-3β activity by phosphorylation of its Ser9 residue. GSK-3 β has a critical role in the regulation of the amount of cyclin D1, as this kinase is involved in both cyclin D1 mRNA transcription and ubiquitin-dependent proteolysis. Participates in the Wnt signaling pathway. Implicated in the hormonal control of several regulatory proteins including glycogen synthase, MYB and the transcription factor JUN. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates MUC1 in breast cancer cells, and decreases the interaction of MUC1 with CTNNB1/β-catenin. Phosphorylates CTNNB1/β-catenin.
Product References
1) Blankesteijn WM et al., (2008) Trends Pharmacol Sci 29(4):175-80. (General)
2) Sugden PH et al., (2008) Br J Pharmacol 153 Suppl 1:S137-53. (General)
3) Takahashi-Yanaga F and Sasaguri T, (2008) Cell Signal 20(4):581-9. (General)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.